Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Alphatec Holdings, Inc. (ATEC)

7.07 -4.31 (-37.86%)
As of 12:49:59 PM EDT. Market Open.
Trade ATEC on Coinbase
ATEC Q3 2026 earnings call
Replay the call for the latest insights.
Chart Range Bar
Loading chart for ATEC
  • Previous Close 11.37
  • Open 6.86
  • Bid 6.85 x 100
  • Ask 8.80 x 200
  • Day's Range 6.81 - 8.02
  • 52 Week Range 6.81 - 23.29
  • Volume 14,978,996
  • Avg. Volume 2,396,581
  • Market Cap (intraday) 1.091B
  • Beta (5Y Monthly) 0.78
  • PE Ratio (TTM) --
  • EPS (TTM) -0.72
  • Earnings Date Oct 29, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 15.57
  • Zacks Rating Neutral

Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. The company manufactures and sells implants, instruments, imaging equipment, and spare parts. It offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; SafeOp Neural InformatiX System that automates electromyographic, somatosensory evoked potential, and motor evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissue; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. The company was founded in 1990 and is headquartered in Carlsbad, California.

www.atecspine.com

913

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ATEC
66.42%
S&P 500 (^GSPC)
10.81%

1-Year Return

ATEC
56.74%
S&P 500 (^GSPC)
11.19%

3-Year Return

ATEC
20.53%
S&P 500 (^GSPC)
82.04%

5-Year Return

ATEC
39.77%
S&P 500 (^GSPC)
64.71%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 221.17M
Earnings -5.47M
Profit Margin -2.47%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
50M
100M
150M
200M
-15.0%
-10.0%
-5.0%

Analyst Insights

View More

Analyst Price Targets

10.00
15.57 Average
7.07 Current
24.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/30/2026
Analyst Needham
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 14 -> 12

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -13.49%

  • Return on Assets (ttm)

    -3.07%

  • Return on Equity (ttm)

    -373.44%

  • Revenue (ttm)

    815.05M

  • Net Income Avi to Common (ttm)

    -109.99M

  • Diluted EPS (ttm)

    -0.72

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    118.66M

  • Total Debt/Equity (mrq)

    5,236.90%

  • Levered Free Cash Flow (ttm)

    48.31M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: